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Using CamGrid to model the 
evolution of Influenza 
Influenza virus: pandemic and epidemic
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The Influenza Virus
Annually, 'flu infects 5-15% of the global 
population (~600 million people)
Virus genome contains 8 RNA segments 
which code 11 proteins 
 
RNA polymerase makes a single 
nucleotide error roughly every 13 
thousand nucleotides
  
Nearly every new influenza virus has a 
mutation thus is highly antigenically 
variable 
Over time, mutations build up and 
antibodies lose the ability to bind. 
For this reason, the 'flu vaccine has had to 
be updated more than 20 times over the 
last 40 years. 
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Haemagglutinin
Protein expressed on surface of virus 
The major component of the 'flu vaccine
The main focus of global 'flu surveillance
There are ~500 HA proteins on surface of virus
HA binds to sugars on the surface of the cell 
Antigenic Variation  
Genetic changes which lead to vaccine breakdown
Species Specificity  
Binding preference (human/avian) and zoonotic potential 
 
What are we interested in modelling? 
Antigenic differences among strains of influenza virus
Haemagglutinin-inhibition (HI) assay data
  
 A genotype to phenotype map for HA
 Two dimensional
 Mostly linear 
 Forms Clusters
 Chronologically ordered  
 Equal time between clusters
 Equal distance between clusters
 “Antigenic map” of Influenza H3N2 1968-2003
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In silico predictions of the structure of the virus
Model strain
of interest
Xray structure of a strain of HA
Molecular Dynamics or 
Monte Carlo simulations
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In Silico Genotype to phenotype prediction of the evolution of HA 
Given the sequence (genotype) of any 
HA ,we could predict its tertiary 
structure and its phenotype and position 
on the 'map'. 
Predict which mutations would alter its 
phenotype.
This would aid surveillance and vaccine 
selection
Pre-emptive vaccination could be used 
to block the virus from moving in a 
particular direction
Antigenic Variation  
Genetic changes which lead to vaccine breakdown
Species Specificity  
Binding preference (human/avian) and zoonotic potential 
 
What are we interested in modelling? 
  
α-2,6 linkage
Human & Pig 
adapted influenza 
viruses
Avian, Equine & Pig 
adapted influenza 
viruses 
Determinants of ligand specificity
Sialic acid
galactose
N-Acetyl 
Glucoosamine
α-2,3 linkage
  
 Binding Mode 1
 Binding Mode 2
Add ligand from xray data
In silico predictions of ligand binding
  
Intro for SC1918
Stevens et al. J Mol Biol. 2006  355(5):1143-55
Sugar binding properties of H1N1 A/South Carolina/1/1918
A/South Carolina/1/1918 A/South Carolina/1/1918
+ D222G
The single mutation D222G 
Gains binding to sulphated α2,3 glycans (increased mortality)
Loses binding to α2,6 glycans (poor transmission)
How does the D222G mutation affect binding in 2009 pdm H1N1 strain?
  
Molecular Dynamics of A/South Carolina/1/1918 with α2,6 glycan
Ala224
~1300 structures extracted from each simulation
Asp222
mode 1                  mode 2
  
A/South Carolina/1/1918 +D222G A/South Carolina/1/1918 
Main interactions with sidechain of D222 
and D187
D222G Reduces possible interactions
Hydrogen binding frequencies involving ligand 
D222G strain makes fewer interactions with α2,6 glycan than wild type.
  
2009 pdmH1N1 A/NL/602/2009
More continuous distribution between two modes
mode 1                  mode 2
  
PDM A/Netherlands/602/09 A/South Carolina/1/1918 
Genetic differences provides extra networks of 
interactions which stabilise intermediate binding mode
  
A/Netherlands/602/09 A/Netherlands/602/09+D222G
Decrease of 222 interactions compensated for by increase in 
interactions with E224, S183 and K130.  
  
A/Netherlands/602/09
+D222G
A/South Carolina/1/1918
+D222G 
We would predict that, unlike A/SC/1918+D222G, A/Netherlands/602/09+D222G 
binds just as well as A/Netherlands/602/09 
  
Two distinct binding modes of the galactose sugar for SC1918
A more continuous distribution for A/Netherlands/602/09
A role for E224, S183, K130 in binding
Reduction of interactions for SC1918+D222G
Conservation of binding for A/Netherlands/602/09+D222G
Predictions from the MD simulation
  
Hua Yang, Paul Carney, and James Stevens. 
Structure and Receptor binding properties of a pandemic H1N1 virus hemagglutinin. 
PLoS Curr Influenza. 2010 
2009 PDM + D222G maintains α2,6 binding
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Future Work 
Improvements in quantitative binding calculations
 
Investigate binding to α2,3 glycans
Investigate evidence for multiple binding modes 
More robust docking and sampling of the glycans into the RBS
Longer simulations for benchmark set for improved statistics
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